TY - JOUR
T1 - Preferences and User Experiences of Wearable Devices in Epilepsy
T2 - A Systematic Review and Mixed-Methods Synthesis
AU - Sivathamboo, Shobi
AU - Nhu, Duong
AU - Piccenna, Loretta
AU - Yang, Anthony
AU - Antonic-Baker, Ana
AU - Vishwanath, Swarna
AU - Todaro, Marian
AU - Yap, Lim Wei
AU - Kuhlmann, Levin
AU - Cheng, Wenlong
AU - O'Brien, Terence John
AU - Lannin, Natasha A
AU - Kwan, Patrick
N1 - Funding Information:
This study was funded by the Australian Medical Research Future Fund (MRF1136427), the National Heart Foundation (GNT102005), and the Victorian Medical Research Acceleration Fund.
Funding Information:
S. Sivathamboo is supported by a Bridging Postdoctoral Fellowship from Monash University (BPF20-3253672466) and the Victorian Medical Research Acceleration Fund. She reports salary support from Kaoskey and Optalert paid to her institutions for clinical trial–related activities; she receives no personal income for these activities. L. Kuhlmann is supported by a project grant from the National Health and Medical Research Council (GNT1160815). W. Cheng is currently supported by Australian Research Council discovery projects (DP200100624 and DP210101045) and a project grant from the National Health and Medical Research Council (APP2004444). He also reports a successful Investigator Grant (APP2010154) from the National Health and Medical Research Council, which is to be started in 2022. He is the founder of the start-up company Soft Sense Pty Ltd. T.J. O'Brien is supported by a program grant (APP1091593) and investigator grant (APP1176426) from the National Health and Medical Research Council of Australia and the Victorian Medical Research Acceleration Fund. He reports grants and personal fees paid to his institutions from Eisai, UCB Pharma, Praxis, Biogen, ES Therapeutics, and Zynerba. N.A. Lannin is supported by a fellowship from the National Heart Foundation (GNT102005), and she reports no further relevant disclosures. P. Kwan is supported by a Medical Research Future Fund Practitioner Fellowship (MRF1136427) and the Victorian Medical Research Acceleration Fund. He reports grants and personal fees from Eisai, UCB Pharma, and LivaNova; reports grants from Zynerba, Biscayne, and GW Pharmaceuticals; and has received travel, speaker honoraria, or consultancy fees from Sun Pharmaceuticals, Supernus Pharmaceuticals, Novartis, and Eisai. The other authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
© American Academy of Neurology.
PY - 2022/9/27
Y1 - 2022/9/27
N2 - Background and ObjectivesTo examine the preferences and user experiences of people with epilepsy and caregivers regarding automated wearable seizure detection devices.MethodsWe performed a mixed-methods systematic review. We searched electronic databases for original peer-reviewed publications between January 1, 2000, and May 26, 2021. Key search terms included "epilepsy,""seizure,""wearable,"and "non-invasive."We performed a descriptive and qualitative thematic analysis of the studies included according to the technology acceptance model. Full texts of the discussion sections were further analyzed to identify word frequency and word mapping.ResultsTwenty-two observational studies were identified. Collectively, they comprised responses from 3,299 participants including patients with epilepsy, caregivers, and healthcare workers. Sixteen studies examined user preferences, 5 examined user experiences, and 1 examined both experiences and preferences. Important preferences for wearables included improving care, cost, accuracy, and design. Patients desired real-time detection with a latency of ≤15 minutes from seizure occurrence, along with high sensitivity (≥90%) and low false alarm rates. Device-related costs were a major factor for device acceptance, where device costs of <$300 USD and a monthly subscription fee of <$20 USD were preferred. Despite being a major driver of wearable-based technologies, sudden unexpected death in epilepsy was rarely discussed. Among studies evaluating user experiences, there was a greater acceptance toward wristwatches. Thematic coding analysis showed that attitudes toward device use and perceived usefulness were reported consistently. Word mapping identified "specificity,""cost,"and "battery"as key single terms and "battery life,""insurance coverage,""prediction/detection quality,"and the effect of devices on "daily life"as key bigrams.DiscussionUser acceptance of wearable technology for seizure detection was strongly influenced by accuracy, design, comfort, and cost. Our findings emphasize the need for standardized and validated tools to comprehensively examine preferences and user experiences of wearable devices in this population using the themes identified in this study. Greater efforts to incorporate perspectives and user experiences in developing wearables for seizure detection, particularly in community-based settings, are needed.Trial Registration InformationPROSPERO Registration CRD42020193565.
AB - Background and ObjectivesTo examine the preferences and user experiences of people with epilepsy and caregivers regarding automated wearable seizure detection devices.MethodsWe performed a mixed-methods systematic review. We searched electronic databases for original peer-reviewed publications between January 1, 2000, and May 26, 2021. Key search terms included "epilepsy,""seizure,""wearable,"and "non-invasive."We performed a descriptive and qualitative thematic analysis of the studies included according to the technology acceptance model. Full texts of the discussion sections were further analyzed to identify word frequency and word mapping.ResultsTwenty-two observational studies were identified. Collectively, they comprised responses from 3,299 participants including patients with epilepsy, caregivers, and healthcare workers. Sixteen studies examined user preferences, 5 examined user experiences, and 1 examined both experiences and preferences. Important preferences for wearables included improving care, cost, accuracy, and design. Patients desired real-time detection with a latency of ≤15 minutes from seizure occurrence, along with high sensitivity (≥90%) and low false alarm rates. Device-related costs were a major factor for device acceptance, where device costs of <$300 USD and a monthly subscription fee of <$20 USD were preferred. Despite being a major driver of wearable-based technologies, sudden unexpected death in epilepsy was rarely discussed. Among studies evaluating user experiences, there was a greater acceptance toward wristwatches. Thematic coding analysis showed that attitudes toward device use and perceived usefulness were reported consistently. Word mapping identified "specificity,""cost,"and "battery"as key single terms and "battery life,""insurance coverage,""prediction/detection quality,"and the effect of devices on "daily life"as key bigrams.DiscussionUser acceptance of wearable technology for seizure detection was strongly influenced by accuracy, design, comfort, and cost. Our findings emphasize the need for standardized and validated tools to comprehensively examine preferences and user experiences of wearable devices in this population using the themes identified in this study. Greater efforts to incorporate perspectives and user experiences in developing wearables for seizure detection, particularly in community-based settings, are needed.Trial Registration InformationPROSPERO Registration CRD42020193565.
KW - epilepsy
KW - wearables
UR - http://www.scopus.com/inward/record.url?scp=85139664323&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000200794
DO - 10.1212/WNL.0000000000200794
M3 - Review Article
C2 - 35705497
AN - SCOPUS:85139664323
SN - 0028-3878
VL - 99
SP - e1380-e1392
JO - Neurology
JF - Neurology
IS - 13
ER -